
|Videos|April 11, 2014
Sequencing and Combining Idelalisib and Ibrutinib
Author(s)Anas Younes, MD
Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the prospect of sequencing or combining idelalisib and ibrutinib in lymphoid malignancies.
Advertisement
Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the prospect of sequencing or combining idelalisib and ibrutinib in lymphoid malignancies.
Clinical Pearls:
- Right now, there is no guidance on how to sequence the two agents
- Ibrutinib should not be given to patients on anticoagulation agents, such as Coumadin
- Side effect patterns will help physicians decide which agent a patient should receive
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5








































